Booster Shots

Oddities, musings and news from the health world

« Previous Post | Booster Shots Home | Next Post »

Rodent of the Week: A topical treatment for herpes

January 23, 2009 |  2:00 pm

Rodent_of_the_weekGenital herpes affects about 536 million people worldwide, which means the virus really gets around. There is no cure for herpes, but oral medications exist to help prevent transmission of the virus from an infected partner to a non-infected partner. Someday, however, a highly reliable topical treatment to stop transmission may be available.

Researchers reported in Thursday's edition of the journal Cell Host & Microbe that they have created a topical treatment that prevents the transmission of herpes simplex virus type 2 (the most common strain) in mice. Moreover, the treatment, called a microbicide, prevented spread of the virus when it was applied from one week before sexual intercourse to a few hours before. Previous experimental microbicides to prevent herpes have required application just before sexual intercourse.

The study, led by Dr. Judy Lieberman of Harvard Medical School, developed a topic treatment that, in mice, disabled key genes necessary for herpes transmission. The researchers first used a natural process called RNA interference to switch off specific genes that allow the herpes virus to replicate. RNA interference occurs in the cells of multicellular organisms to regulate the translation of genetic information into proteins. Scientists have great interest in using this process to create new medications but have found it difficult to coax the RNA molecules into specific cells. Lieberman's group fused RNA with cholesterol molecules, which allowed it to be absorbed into vaginal tissues and into the cell membranes.

"People have been trying to make a topical agent that can prevent transmission, a microbicide, for many years," Lieberman said in a news release. "But one of the main obstacles for this is compliance. One of the attractive features of the compound we developed is that it creates in the tissue a state that's resistant to infection, even if applied up to a week before sexual exposure. This aspect has a real practicality to it. If we can reproduce these results in people, this could have a powerful impact on preventing transmission."

   The treatment did not cause any serious side effects in mice. Lieberman recently received a grant to collaborate with a corporate partner in developing a topical microbicide for human use. She is also examining whether the same approach might be used to treat HIV infection.

-- Shari Roan

Photo: Advanced Cell Technology Inc.

Post a comment
If you are under 13 years of age you may read this message board, but you may not participate.
Here are the full legal terms you agree to by using this comment form.

Comments are moderated, and will not appear until they've been approved.

If you have a TypeKey or TypePad account, please Sign In

Comments (1)

Alnylam (ALNY) is the company involved in this work and is the leading company in the RNAi space. RNAi shows huge promise to be the next big medical platform with the potential to effectively treat a wide-range of ailments and cancers. Here's a link to a PBS NOVA special explaining RNAi in very easy-to-understand language:


The Latest | news as it happens

Recent Posts
test |  March 15, 2011, 4:00 pm »
Booster Shots has moved |  July 12, 2010, 6:02 pm »